Eyeworld

SUMMER 2025

EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.

Issue link: https://digital.eyeworld.org/i/1536325

Contents of this Issue

Navigation

Page 9 of 82

Bimatoprost (Bimatoprost 0.01%) Dorzolamide (Dorzolamide 2%) Brim-Dor® (Brimonidine and dorzolamide, 0.15/2%) Tim-Bim™ (Timolol and bimatoprost, 0.5/0.01%) Tim-Dor-Bim™ (Timolol, dorzolamide and bimatoprost, 0.5/2/0.15%) Tim-Brim-Dor® (Timolol, brimonidine and dorzolamide, 0.5/0.15/2%) Tim-Brim-Dor-Bim™ (Timolol, brimonidine, dorzolamide and bimatoprost, 0.5/0.15/2/0.01%) PRESERVATIVEFREE TOPICAL FORMULATIONS* KEEP IT SIMPLE WITH *For professional use only. ImprimisRx specializes in customizing medications to meet unique patient and practitioner needs. ImprimisRx dispenses these formulations only to individually identied patients with valid prescriptions. No compounded medication is reviewed by the FDA for safety or efcacy. ImprimisRx does not compound essential copies of commercially available products. These ingredients carry risks. Visit imprimisrx.com/productinformation for full product details. References available upon request. Harrow IP, LLC owns the ImprimisRx logo trademarks. ©2025 ImprimisRx. All Rights Reserved. SD-00033 05/25 VISIT WWW.SIMPLEDROPS.COM OR SCAN THE QR CODE TO LEARN MORE Important: Patients may need to take more than one eye drop medication pursuant to multiple dosing regimens, as directed by his or her prescriber, in order for the active ingredients to remain effective throughout the day.

Articles in this issue

Links on this page

Archives of this issue

view archives of Eyeworld - SUMMER 2025